Evotec SE has announced a $25m milestone payment from Bristol Myers Squibb, recognising scientific progress made within their strategic neuroscience partnership.
The funds will support continued development of the companies’ joint preclinical pipeline targeting neurodegenerative diseases.
The collaboration, launched in 2016, aims to discover and develop disease-modifying treatments for conditions where current therapies remain limited.
Since inception, the partnership has produced a robust pipeline of innovative programmes, including EVT8683 – in-licensed by Bristol Myers Squibb in 2021 as BMS-986419 – which has successfully completed phase 1 clinical trials.
In 2023, the partnership was extended for a further eight years, underlining both companies’ commitment to advancing transformative therapies.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “Patients living with neurodegenerative conditions urgently need therapies that go beyond the management of symptoms. This achievement increases the depth of our collaboration with Bristol Myers Squibb.”
He added: “Together, we are translating emerging disease biology into potential therapeutic opportunities, with the goal of providing meaningful new options for patients suffering from neurodegenerative diseases.”
